Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Colorectal Cancer

Health Behaviors in Patients Who Have Finished Treatment for Stage I, Stage II, or Stage III Colorectal Cancer
Health Behaviors Among Individuals Diagnosed With Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
2373
mi
from 98109
Philadelphia, PA
Health Behaviors in Patients Who Have Finished Treatment for Stage I, Stage II, or Stage III Colorectal Cancer
Health Behaviors Among Individuals Diagnosed With Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
Fox Chase Cancer Center
2373
mi
from 98109
Philadelphia, PA
Click here to add this to my saved trials
Health Behaviors in Patients Who Have Finished Treatment for Stage I, Stage II, or Stage III Colorectal Cancer
Health Behaviors Among Individuals Diagnosed With Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
1892
mi
from 98109
Houston, TX
Health Behaviors in Patients Who Have Finished Treatment for Stage I, Stage II, or Stage III Colorectal Cancer
Health Behaviors Among Individuals Diagnosed With Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center
1892
mi
from 98109
Houston, TX
Click here to add this to my saved trials
Health Behaviors in Patients Who Have Finished Treatment for Stage I, Stage II, or Stage III Colorectal Cancer
Health Behaviors Among Individuals Diagnosed With Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
2417
mi
from 98109
Neptune, NJ
Health Behaviors in Patients Who Have Finished Treatment for Stage I, Stage II, or Stage III Colorectal Cancer
Health Behaviors Among Individuals Diagnosed With Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
Jersey Shore University Medical Center
2417
mi
from 98109
Neptune, NJ
Click here to add this to my saved trials
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects With Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
669
mi
from 98109
Stockton, CA
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects With Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
669
mi
from 98109
Stockton, CA
Click here to add this to my saved trials
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects With Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
2701
mi
from 98109
Boynton Beach, FL
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects With Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2701
mi
from 98109
Boynton Beach, FL
Click here to add this to my saved trials
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects With Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
1435
mi
from 98109
Wichita, KA
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects With Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1435
mi
from 98109
Wichita, KA
Click here to add this to my saved trials
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects With Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
1743
mi
from 98109
Temple, TX
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects With Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1743
mi
from 98109
Temple, TX
Click here to add this to my saved trials
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects With Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
678
mi
from 98109
Ogden, UT
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects With Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
678
mi
from 98109
Ogden, UT
Click here to add this to my saved trials
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects With Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
7763
mi
from 98109
Liverpool,
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of Panitumumab and Cetuximab in Subjects With Previously Treated, Wild-type KRAS, Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
7763
mi
from 98109
Liverpool,
Click here to add this to my saved trials
Does Inspection During Insertion Improve Adenoma Yields During Colonoscopy?
Does Inspection During Insertion Improve Adenoma Yields During Colonoscopy?
Status: Enrolling
Updated:  12/31/1969
1863
mi
from 98109
Indianapolis, IN
Does Inspection During Insertion Improve Adenoma Yields During Colonoscopy?
Does Inspection During Insertion Improve Adenoma Yields During Colonoscopy?
Status: Enrolling
Updated: 12/31/1969
Beltway Surgery Center
1863
mi
from 98109
Indianapolis, IN
Click here to add this to my saved trials
Does Inspection During Insertion Improve Adenoma Yields During Colonoscopy?
Does Inspection During Insertion Improve Adenoma Yields During Colonoscopy?
Status: Enrolling
Updated:  12/31/1969
1867
mi
from 98109
Indianapolis, IN
Does Inspection During Insertion Improve Adenoma Yields During Colonoscopy?
Does Inspection During Insertion Improve Adenoma Yields During Colonoscopy?
Status: Enrolling
Updated: 12/31/1969
Indiana University Hospital
1867
mi
from 98109
Indianapolis, IN
Click here to add this to my saved trials
A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer
A Phase II Study of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP) in Combination With Temozolomide in Patients With Heavily Pretreated, Metastatic Colorectal Cancer
Status: Enrolling
Updated:  12/31/1969
2322
mi
from 98109
Washington,
A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer
A Phase II Study of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP) in Combination With Temozolomide in Patients With Heavily Pretreated, Metastatic Colorectal Cancer
Status: Enrolling
Updated: 12/31/1969
Georgetown University Medical Center
2322
mi
from 98109
Washington,
Click here to add this to my saved trials
Panitumumab and Bevacizumab Maintenance After First-Line FOLFOX-Bevacizumab for Patients With Advanced Colorectal Cancer With Wild-Type Ras
Panitumumab and Bevacizumab Maintenance After First-Line FOLFOX-Bevacizumab for Patients With Advanced Colorectal Cancer With Wild-Type Ras
Status: Enrolling
Updated:  12/31/1969
2486
mi
from 98109
Providence, RI
Panitumumab and Bevacizumab Maintenance After First-Line FOLFOX-Bevacizumab for Patients With Advanced Colorectal Cancer With Wild-Type Ras
Panitumumab and Bevacizumab Maintenance After First-Line FOLFOX-Bevacizumab for Patients With Advanced Colorectal Cancer With Wild-Type Ras
Status: Enrolling
Updated: 12/31/1969
Rhode Island Hospital
2486
mi
from 98109
Providence, RI
Click here to add this to my saved trials
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
959
mi
from 98109
Beverly Hills, CA
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
959
mi
from 98109
Beverly Hills, CA
Click here to add this to my saved trials
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
1041
mi
from 98109
Encinitas, CA
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1041
mi
from 98109
Encinitas, CA
Click here to add this to my saved trials
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
988
mi
from 98109
Fountain Valley, CA
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
988
mi
from 98109
Fountain Valley, CA
Click here to add this to my saved trials
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
980
mi
from 98109
Riverside, CA
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
980
mi
from 98109
Riverside, CA
Click here to add this to my saved trials
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
988
mi
from 98109
Fort Collins, CO
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
988
mi
from 98109
Fort Collins, CO
Click here to add this to my saved trials
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
2464
mi
from 98109
Norwich, CT
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2464
mi
from 98109
Norwich, CT
Click here to add this to my saved trials
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
2701
mi
from 98109
Boynton Beach, FL
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2701
mi
from 98109
Boynton Beach, FL
Click here to add this to my saved trials
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
2616
mi
from 98109
Fort Myers, FL
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2616
mi
from 98109
Fort Myers, FL
Click here to add this to my saved trials
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
2544
mi
from 98109
Orlando, FL
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2544
mi
from 98109
Orlando, FL
Click here to add this to my saved trials
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
1773
mi
from 98109
Centralia, IL
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1773
mi
from 98109
Centralia, IL
Click here to add this to my saved trials
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
2091
mi
from 98109
Metairie, LA
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2091
mi
from 98109
Metairie, LA
Click here to add this to my saved trials
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
2328
mi
from 98109
Baltimore, MD
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2328
mi
from 98109
Baltimore, MD
Click here to add this to my saved trials
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
2265
mi
from 98109
Hagerstown, MD
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2265
mi
from 98109
Hagerstown, MD
Click here to add this to my saved trials
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
1366
mi
from 98109
Omaha, NE
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1366
mi
from 98109
Omaha, NE
Click here to add this to my saved trials
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
2110
mi
from 98109
Buffalo, NY
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2110
mi
from 98109
Buffalo, NY
Click here to add this to my saved trials
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
2414
mi
from 98109
Lake Success, NY
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2414
mi
from 98109
Lake Success, NY
Click here to add this to my saved trials
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
2052
mi
from 98109
Canton, OH
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2052
mi
from 98109
Canton, OH
Click here to add this to my saved trials
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
1967
mi
from 98109
Cincinnati, OH
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1967
mi
from 98109
Cincinnati, OH
Click here to add this to my saved trials
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
1523
mi
from 98109
Oklahoma City, OK
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1523
mi
from 98109
Oklahoma City, OK
Click here to add this to my saved trials
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
2424
mi
from 98109
Charleston, SC
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2424
mi
from 98109
Charleston, SC
Click here to add this to my saved trials
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
2321
mi
from 98109
Columbia, SC
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2321
mi
from 98109
Columbia, SC
Click here to add this to my saved trials
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
1970
mi
from 98109
Nashville, TN
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1970
mi
from 98109
Nashville, TN
Click here to add this to my saved trials
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
1890
mi
from 98109
Houston, TX
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1890
mi
from 98109
Houston, TX
Click here to add this to my saved trials
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
2
mi
from 98109
Seattle, WA
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
5186
mi
from 98109
Bayonne,
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
A Randomized, Placebo-Controlled, Phase 1/2 Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
5186
mi
from 98109
Bayonne,
Click here to add this to my saved trials
Personalized Prevention of Colorectal Cancer Trial
Investigational Nutrigenetic Studies for Cancer Prevention
Status: Enrolling
Updated:  12/31/1969
1971
mi
from 98109
Nashville, TN
Personalized Prevention of Colorectal Cancer Trial
Investigational Nutrigenetic Studies for Cancer Prevention
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center
1971
mi
from 98109
Nashville, TN
Click here to add this to my saved trials
Sym004 in Patients With Advanced Solid Tumors
An Open-label, Multi-center Phase I Dose Escalation Study to Investigate the Safety and Tolerability of Multiple Doses of Sym004 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
1780
mi
from 98109
San Antonio, TX
Sym004 in Patients With Advanced Solid Tumors
An Open-label, Multi-center Phase I Dose Escalation Study to Investigate the Safety and Tolerability of Multiple Doses of Sym004 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
South Texas Accelerated Research Therapeutics
1780
mi
from 98109
San Antonio, TX
Click here to add this to my saved trials
Sym004 in Patients With Advanced Solid Tumors
An Open-label, Multi-center Phase I Dose Escalation Study to Investigate the Safety and Tolerability of Multiple Doses of Sym004 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
4933
mi
from 98109
Brussel,
Sym004 in Patients With Advanced Solid Tumors
An Open-label, Multi-center Phase I Dose Escalation Study to Investigate the Safety and Tolerability of Multiple Doses of Sym004 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
UZ Brussel, Medische Oncologie
4933
mi
from 98109
Brussel,
Click here to add this to my saved trials
Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor
A Phase 1 Open-Label, Dose-Escalation Study of Veliparib in Combination With Bimonthly FOLFIRI in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
1970
mi
from 98109
Nashville, TN
Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor
A Phase 1 Open-Label, Dose-Escalation Study of Veliparib in Combination With Bimonthly FOLFIRI in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1970
mi
from 98109
Nashville, TN
Click here to add this to my saved trials
Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor
A Phase 1 Open-Label, Dose-Escalation Study of Veliparib in Combination With Bimonthly FOLFIRI in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
1117
mi
from 98109
Scottsdale, AZ
Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor
A Phase 1 Open-Label, Dose-Escalation Study of Veliparib in Combination With Bimonthly FOLFIRI in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1117
mi
from 98109
Scottsdale, AZ
Click here to add this to my saved trials
Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor
A Phase 1 Open-Label, Dose-Escalation Study of Veliparib in Combination With Bimonthly FOLFIRI in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
962
mi
from 98109
Los Angeles, CA
Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor
A Phase 1 Open-Label, Dose-Escalation Study of Veliparib in Combination With Bimonthly FOLFIRI in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
962
mi
from 98109
Los Angeles, CA
Click here to add this to my saved trials
Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor
A Phase 1 Open-Label, Dose-Escalation Study of Veliparib in Combination With Bimonthly FOLFIRI in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
2322
mi
from 98109
Washington,
Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor
A Phase 1 Open-Label, Dose-Escalation Study of Veliparib in Combination With Bimonthly FOLFIRI in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2322
mi
from 98109
Washington,
Click here to add this to my saved trials
Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor
A Phase 1 Open-Label, Dose-Escalation Study of Veliparib in Combination With Bimonthly FOLFIRI in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
2341
mi
from 98109
Durham, NC
Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor
A Phase 1 Open-Label, Dose-Escalation Study of Veliparib in Combination With Bimonthly FOLFIRI in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2341
mi
from 98109
Durham, NC
Click here to add this to my saved trials
Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor
A Phase 1 Open-Label, Dose-Escalation Study of Veliparib in Combination With Bimonthly FOLFIRI in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
6647
mi
from 98109
Seoul,
Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor
A Phase 1 Open-Label, Dose-Escalation Study of Veliparib in Combination With Bimonthly FOLFIRI in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
6647
mi
from 98109
Seoul,
Click here to add this to my saved trials
Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
HOPE Program: Quality of Life Enhancement and Survivorship Care
Status: Enrolling
Updated:  12/31/1969
2279
mi
from 98109
Winston-Salem, NC
Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
HOPE Program: Quality of Life Enhancement and Survivorship Care
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences
2279
mi
from 98109
Winston-Salem, NC
Click here to add this to my saved trials
Survivorship in Lynch Syndrome Families
Cancer Survivorship in Lynch Syndrome: Impact on Patients and Families
Status: Enrolling
Updated:  12/31/1969
1892
mi
from 98109
Houston, TX
Survivorship in Lynch Syndrome Families
Cancer Survivorship in Lynch Syndrome: Impact on Patients and Families
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
1892
mi
from 98109
Houston, TX
Click here to add this to my saved trials
A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum
A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum
Status: Enrolling
Updated:  12/31/1969
2315
mi
from 98109
Bethesda, MD
A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum
A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
2315
mi
from 98109
Bethesda, MD
Click here to add this to my saved trials